Targeting tumor vasculature with homing peptides from phage display
Abstract
Tumor vasculature expresses a number of molecular markers at much lower levels than those seen in the blood vessels of normal tissues, and in some cases, such markers are undetectable. The presence of these markers relates to angiogenesis; the same markers are shared by all blood vessels undergoing angiogenesis. The endothelial cells, pericytes and smooth muscle cells, and the vascular extracellular matrix in angiogenic vessels can each express such markers. Molecularly, they represent vascular growth factor receptors, cell adhesion proteins and their receptors. Screening of phage display libraries for peptides that home to tumor vasculature when injected into mice has recently provided a new tool for analyzing the distinguishing features of tumor vasculature. Tumor-homing peptides isolated in this manner, as well as an antibody against a form of fibronectin expressed in tumor blood vessels, have been found to serve as targeting devices to concentrate drugs and other therapeutic materials to tumors in in vivo models. Such a targeting strategy can therefore potentially improve the efficacy of drugs and reduce their side effects.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Phages can remodel the tumor microenvironment.
“Phages can eliminate cancer-associated bacteria, remodel the tumor microenvironment, enhance antitumor immunity, and deliver targeted therapeutic payloads.”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [50]
Engineered phages can be designed to selectively target key tumor microenvironment components, including tumor-associated macrophages, cancer-associated fibroblasts, and the tumor vasculature.
“Engineered phages can be designed to selectively target key TME components, including tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and the tumor vasculature (Box 3) [15,48–50]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [50]
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191 · see citing works
Self-citationAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · see citing works
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works
Developments in liposomal drug delivery systems
Maurer, N., Fenske, D. B., & Cullis, P. R. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.6.923 · Cited by 344 · see citing works
Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Wang, S., Placzek, W. J., Stebbins, J. L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E. B., & Pellecchia, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201743s · Cited by 94 · see citing works
Phage therapy in oncology: opportunities for cancer prevention and treatment
Mutalik, V. K., Inman, J. L., Chang, H., Arkin, A., & Mao, J.-H. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.02.001 · Cited by 5 · see citing works
- Authors
- Ruoslahti, E.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Ruoslahti, Erkki
- ORCID
- Ruoslahti, Erkki
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 10
- Issue
- 6
- Pages
- 435-442
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W1989414395
- Cited by
- 157
- References
- 3
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 4 · 2022: 5 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 6 · 2017: 4 · 2016: 4 · 2015: 8 · 2014: 5 · 2013: 5 · 2012: 9
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Cancer Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01ca074238-01)
- National Cancer Institute (CA 74238, CA30199, P30CA030199)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- tumor vasculature, tumor-homing peptides, phage display, angiogenesis, fibronectin, targeted drug delivery, tumor targeting, adhesion molecules, pericytes, vascular extracellular matrix
- MeSH terms
- Endothelium, Vascular, Humans, Neoplasms, Neovascularization, Pathologic, Oligopeptides, Peptide Library
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review